Antibiotic-induced rash is a notable complication that can occur in individuals with Epstein-Barr virus (EBV)-associated acute infectious mononucleosis (AIM). Initial reports suggested a very high incidence of such rashes, ranging from 80% to 100% in children diagnosed with AIM. However, a more recent study re-evaluated this incidence and found it to be significantly lower, with antibiotic-induced rash occurring in approximately 33% of study participants.
Among the antibiotics studied, patients treated with amoxicillin were found to be significantly more likely to develop a drug-induced rash compared to those treated with other antibiotics. The incidence of rash was highest among patients taking amoxicillin (29.5%), followed by amoxicillin and clavulanate (15.5%), cephalosporins (15.4%), macrolides (9%), and penicillin (8.5%).
The study also identified certain clinical markers that were more common among patients who did not develop a rash. These included elevated white blood cell counts, difficulty swallowing, and submandibular lymphadenopathy. Interestingly, there was no association found between an increased risk of rash development and a past history of atopic disease or previous exposure to penicillin.
The precise etiology of antibiotic-associated rash in the context of AIM remains unclear, and the underlying pathogenesis has yet to be fully elucidated. While the study evaluated epidemiological and clinical markers associated with rash development, it did not delve into the deeper biological mechanisms.
Study Design and Patient Cohort
This in-depth retrospective study evaluated 238 patients, aged between 0 and 18 years, who were diagnosed with AIM at two tertiary-level pediatric medical centers. The diagnosis was confirmed by positive immunoglobulin M viral capsid serology. Of these patients, 173 received antibiotic treatment. Among those treated with antibiotics, 41 patients (32.9%) developed an antibiotic-induced rash. The rash was defined as its onset after the administration of the antibiotic and up to 48 hours after the final dose.
Demographic data did not reveal significant differences between patients who developed a rash and those who did not.
Clinical Presentation and Differential Diagnosis
Infectious mononucleosis, commonly caused by EBV, typically affects young adults aged 15-25 years. The classic symptoms include fever, sore throat, and swollen lymph nodes. A generalized maculopapular rash can be a manifestation of infectious mononucleosis itself. However, a more intense and widespread cutaneous eruption may appear in a significant percentage of patients (up to 90%) 2-10 days after starting antibiotic therapy. These antibiotics can include ampicillin, azithromycin, amoxicillin, cephalosporins, tetracyclines, and macrolides like erythromycin.
A case example describes a 23-year-old woman who developed a generalized pruritic rash 17 days after the onset of symptoms suggestive of mononucleosis, including neck swelling, fever, and sore throat. She was treated with amoxicillin for a presumed group A Streptococcus infection. The rash appeared on the day she completed her amoxicillin course. Physical examination revealed tonsillar enlargement, posterior cervical lymphadenopathy, and a maculopapular exanthem involving the face, trunk, and limbs, including palms and soles.
Laboratory tests in this patient showed an elevated white blood cell count with atypical lymphocytes, and positive IgM and IgG antibodies to EBV capsid antigen, confirming a diagnosis of infectious mononucleosis. The diagnosis of amoxicillin rash against a background of infectious mononucleosis was made. All symptoms resolved within 10 days of outpatient follow-up.
Differential Diagnosis Considerations
The differential diagnosis of skin lesions in patients with infectious mononucleosis includes conditions such as Gianotti-Crosti syndrome, Stevens-Johnson syndrome, and other viral infections like varicella-zoster virus and enterovirus. It is important to note that not all these conditions present with the same rash characteristics.
Co-infection with Group A Streptococcus
Group A streptococcal infection can co-occur with infectious mononucleosis. Antimicrobial therapy is often indicated for bacterial infections, placing patients with coinfection at risk for amoxicillin rash. Studies suggest that a considerable percentage of children with acute group A streptococcal pharyngitis may have an EBV coinfection. While distinguishing between true coinfection and mere colonization can be challenging, administering antibiotics for confirmed symptomatic group A streptococcal pharyngitis is generally considered reasonable to prevent complications like rheumatic fever and reduce infection transmission, even in the presence of possible EBV coinfection.
Historical vs. Current Incidence of Amoxicillin Rash
The incidence of amoxicillin rash in patients with infectious mononucleosis has historically been reported as high as 95%. However, recent studies indicate a much lower incidence, typically ranging from 15% to 33%. This discrepancy may be attributed to several factors, including potential contamination of antibiotics in earlier eras or differences in study populations concerning age, ethnicity, and genetics.
While amoxicillin and ampicillin have been associated with a high frequency of rash in patients with infectious mononucleosis, a recent study found that the rash frequency with these agents is similar to that of other antibiotics. This suggests that prescribing alternative non-beta-lactam antibiotics for conditions like group A streptococcal pharyngitis may not necessarily reduce the risk of rash development in patients with concurrent infectious mononucleosis.
Understanding Drug Allergy, Intolerance, and Hypersensitivity
The most widely accepted explanation for amoxicillin rash in infectious mononucleosis is a transient, virus-mediated immune change. This change is thought to decrease antigenic tolerance, leading to a delayed-type hypersensitivity reaction to the antibiotic. This transient immunostimulation is distinct from a true beta-lactam allergy.
An amoxicillin rash occurring during an infectious mononucleosis episode may not necessarily indicate a true penicillin allergy. However, reliable data on the recurrence of rash after re-administration of a beta-lactam antibiotic in patients with a history of amoxicillin rash and infectious mononucleosis are scarce.
Potential for Persistent Drug Hypersensitivity
It is plausible that a true and persistent drug hypersensitivity can develop during the course of infectious mononucleosis. In one study, a significant proportion of patients who developed a rash after aminopenicillin use showed positive amoxicillin patch tests more than three months after their infectious mononucleosis had resolved. It is crucial to acknowledge that this study did not definitively distinguish between pre-existing drug allergies and new hypersensitivity reactions induced by the EBV infection.
Currently, high-quality studies rigorously differentiating these two types of reactions and accurately estimating the risk of persistent drug hypersensitivity following EBV infection are lacking.
Clinical Recommendations
While clinicians should exercise caution in diagnosing penicillin allergy based solely on an amoxicillin rash during an infectious mononucleosis episode, patient involvement in the decision-making process for allergy testing is important. This testing can help differentiate between a transient immunostimulation-related amoxicillin rash and a genuine beta-lactam allergy.
Epstein Barr Virus and Infectious Mononucleosis (pathophysiology, investigations and treatment)
Infectious mononucleosis is a common viral illness primarily caused by EBV. While recovery from the acute phase is typically complete within a few weeks, it can take several months to feel fully well. EBV establishes a lifelong latent infection in memory B cells. Antiviral drugs are generally not effective for uncomplicated cases, and there is no vaccine available against EBV.
tags: #mononucleosis #rash #amoxicillin